- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01930240
The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers (Cortria-002)
July 25, 2016 updated by: Cortria Corporation
A Randomized Placebo Controlled Double Blind Two Period Cross-Over Study to Assess the Safety and Pharmacokinetics and Pharmacodynamics of Oral Dosages of TRIA-662 (A Hypolipidemic Agent) in Healthy Volunteers
The primary objective of the study is to assess the blood profile of the N-methylnicotinamide (MNA) following administration of TRIA-662 (N-methylnicotinamide Chloride).
The secondary objectives of the study are to characterize the safety and tolerability of TRIA-662 and to assess any potential gender-related differences in the plasma profile of MNA.
Changes in serum lipid parameters with particular reference to triglycerides, lipoprotein lipase, and blood pressure effects will also be noted.
Study Overview
Detailed Description
A total of 20 subjects volunteers (10 male and 10 female) will receive the following treatments administered in a randomized fashion with 2 embedded placebo dosages in each group (8 active Males and 8 active females with 2 placebo males and females):
- DRUG (Low Dose): Single therapeutic dose of MNA administered as a 90 mg oral dose
- DRUG (High Dose): Single therapeutic dose of MNA administered as a 270 mg oral dose
- PLACEBO: Placebo for MNA administered as an identically appearing oral dose Each treatment period will consist of a 3-day two-night confinement cycle with admission on day 1, treatment on day 1 with a single dose of active or placebo with discharge 24 hours following the last assessment the next morning. A washout period of 5 days will separate each treatment period. Standard biochemical and clinical baseline medical background and physical examination will occur at screening and at Day -1 to assess/confirm entry criteria. During each treatment period, serial plasma samples (n=12) for MNA assay will be collected on the treatment day. Safety assessments, including vitals signs (blood pressure, pulse rate, respiration rate, and oral body temperature), will be performed at screening, at baseline, and at 4 times throughout each treatment period. Physical examinations and standard clinical laboratory tests (hematology, serum chemistry, and urinalysis) will be obtained at screening, and at admission for each treatment period, and prior to subject's final discharge from the study. The Lunch meals on the dosing day will be identical in each subject on each occasion.
The pharmacokinetic and safety assessments will be performed at specified times prior to and after study MNA administration.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Good health (based on medical history, physical examination, electrocardiogram, and clinical laboratory tests)
- Non-smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the Screening visit)
- Between 18 and 50 years old (inclusive)
- Body weight within 20% of the desirable weight for adults at the Screening visit
- Able to execute informed written consent (informed consent must be obtained for all subjects before enrollment in the study.
- Willingness to abstain from alcohol and xanthine-containing food and beverages for the duration of each treatment period
- Willingness to remain in the clinic for the inpatient portions of the study
- Female subjects must be non-pregnant and either surgically sterile, postmenopausal for a least 1 year, or using an acceptable method of contraception defined as an oral, implanted, or transdermal contraceptive plus one of the following barrier methods: diaphragm with spermicidal cream/jelly or use of a condom by sexual partner.
Exclusion Criteria:
- Currently abusing drugs or alcohol or with a history of drug or alcohol abuse within the past two years
- Unwilling or unable to comply with the protocol or reside in the study unit during the study period or to cooperate fully with the principal investigator and site personnel
- Has used any 1) prescription medication within 14 days prior to treatment in either treatment period or 2), or any over-the-counter (OTC) medication, herbal preparations, and/or vitamins within 48 hours prior to the start of study MNA administration on either treatment period of this study.
- Has a clinically abnormal ECG
- Has a serum potassium, sodium, calcium, or magnesium level that is not within normal limits or has other vital signs or clinical laboratory values at the screening visit that are deemed by the principal investigator to make the subject an inappropriate candidate for the study
- Has taken any other investigational drug during the 30 days prior to screening visit
- Has donated or lost more than a unit of blood within 30 days prior to screening visit
- History of renal, hepatic, gastrointestinal, cardiovascular, or hematologic disease
- Serious mental or physical illness within the past year
- Has any condition(s) that in the investigator's opinion would: a) warrant exclusion from the study or b) prevent the subject from completing the study
- Have a positive test for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody at screening
- Be a female subject with a positive serum pregnancy test or who is breast-feeding at screening
- Be unable to understand verbal and/or written English or any other language in which a certified translation of the informed consent is available
- Has a history of hypersensitivity or allergic reaction to Niacin or Nicotinamide
- Has had prior exposure to MNA
- Has a Mental capacity that is limited to the extent that the subject cannot provide legal consent or understand information regarding the side effects or tolerance of the study drug.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: TRIA-662 Placebo
Single dose of nine placebo capsules matching TRIA-662 drug capsules
|
Double-blind placebo
Other Names:
|
Experimental: TRIA-662 Low Dose
Single-dose of TRIA-662 administered as three 30 mg TRIA-662 capsules and six matching placebo capsules
|
1-MNA Chloride
Other Names:
|
Experimental: TRIA-662 High Dose
Single dose of TRIA-662 administered as nine 30mg TRIA-662 capsules
|
1-MNA Chloride
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MNA Maximum plasma concentration (Cmax).
Time Frame: 0, 1, 2, 3, 4, 5, 8, 12, 18, 24 hours after dose.
|
5 mL venous blood samples will be collected by venipuncture at the specified times.
These blood samples will be properly processed and analyzed for concentration of MNA and metabolites.
The concentration data will undergo typical pharmacokinetic data analysis to arrive at the primary endpoints.
|
0, 1, 2, 3, 4, 5, 8, 12, 18, 24 hours after dose.
|
Time to plasma MNA Cmax
Time Frame: 0, 1, 2, 3, 4, 5, 8, 12, 18, 24 hours after dose.
|
5 mL venous blood samples will be collected by venipuncture at the specified times.
These blood samples will be properly processed and analyzed for concentration of MNA and metabolites.
The concentration data will undergo typical pharmacokinetic data analysis to arrive at the primary endpoints.
|
0, 1, 2, 3, 4, 5, 8, 12, 18, 24 hours after dose.
|
Area under the plasma MNA concentration curve
Time Frame: 0, 1, 2, 3, 4, 5, 8, 12, 18, 24 hours after dose.
|
5 mL venous blood samples will be collected by venipuncture at the specified times.
These blood samples will be properly processed and analyzed for concentration of MNA and metabolites.
The concentration data will undergo typical pharmacokinetic data analysis to arrive at the primary endpoints.
|
0, 1, 2, 3, 4, 5, 8, 12, 18, 24 hours after dose.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2007
Primary Completion (Actual)
January 1, 2008
Study Completion (Actual)
January 1, 2008
Study Registration Dates
First Submitted
August 21, 2013
First Submitted That Met QC Criteria
August 23, 2013
First Posted (Estimate)
August 28, 2013
Study Record Updates
Last Update Posted (Estimate)
July 26, 2016
Last Update Submitted That Met QC Criteria
July 25, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- Cortria-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States